NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
6/8 — Strong
Priority Review
MOUNJARO (AUTOINJECTOR) (tirzepatide) by Eli Lilly and Company is g-protein-linked receptor interactions [moa]. Approved for glucose-dependent insulinotropic polypeptide receptor agonist [epc]. First approved in 2022.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Mounjaro (tirzepatide) autoinjector is a dual GIP/GLP-1 receptor agonist administered subcutaneously for type 2 diabetes management. It works by activating G-protein-linked receptors to enhance glucose-dependent insulin secretion and improve glycemic control. The autoinjector formulation offers convenient, pre-filled weekly dosing for improved patient adherence.
Peak15.2 years to LOE
Product is at peak commercial maturity with strong market penetration; brand teams are focused on maintaining market leadership and managing portfolio variants.
Mechanism of Action
G-Protein-linked Receptor Interactions
Pharmacologic Class:
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Started Jan 2027
70 enrolled
Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication
Started Oct 2026
60 enrolled
OverweightObesityType 2 Diabetes
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Started Sep 2026
150 enrolled
Obesity
Tirzepatide for Treatment of CCCA
Started Sep 2026
20 enrolled
Central Centrifugal Cicatricial Alopecia (CCCA)
A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Started Sep 2026
18 enrolled
Diabetes Mellitus, Type 1OverweightObesity
Worked on MOUNJARO (AUTOINJECTOR) at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.